Q2 2024 · 13F-HR
5AM Venture Management, LLCholdings as filed
Filed 2024-08-14 · accession 0001104659-24-089661
$447.1M
Reported value
28
Positions
2024-06-30
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 83086J200 | SKYE | SKYE BIOSCIENCE INC | $81.5M | 18.2% | 10,179,505 | Common | SOLE |
| 29384C108 | TRDA | ENTRADA THERAPEUTICS INC | $62.8M | 14.1% | 4,408,379 | Common | SOLE |
| 29337E102 | ELVN | ENLIVEN THERAPEUTICS INC | $61.0M | 13.6% | 2,610,875 | Common | SOLE |
| 252828108 | DNTH | DIANTHUS THERAPEUTICS INC | $31.9M | 7.14% | 1,232,965 | Common | SOLE |
| 15117B202 | CLDX | CELLDEX THERAPEUTICS INC NEW | $18.4M | 4.12% | 497,270 | Common | SOLE |
| G1110E107 | BHVN | BIOHAVEN LTD | $16.3M | 3.65% | 469,972 | Common | SOLE |
| 90240B106 | TYRA | TYRA BIOSCIENCES INC | $15.0M | 3.36% | 939,298 | Common | SOLE |
| N69605108 | PHVS | PHARVARIS N V | $15.0M | 3.35% | 797,600 | Common | SOLE |
| 74006W207 | PRAX | PRAXIS PRECISION MEDICINES I | $14.1M | 3.15% | 340,000 | Common | SOLE |
| 29479A108 | ERAS | ERASCA INC | $12.8M | 2.85% | 5,405,404 | Common | SOLE |
| 92686J106 | VKTX | VIKING THERAPEUTICS INC | $12.6M | 2.82% | 237,560 | Common | SOLE |
| 61559X104 | MLTX | MOONLAKE IMMUNOTHERAPEUTICS | $12.4M | 2.78% | 282,313 | Common | SOLE |
| 152309100 | CNTA | CENTESSA PHARMACEUTICALS PLC | $11.2M | 2.51% | 1,245,000 | Common | SOLE |
| 878972108 | TECX | TECTONIC THERAPEUTIC INC | $10.6M | 2.38% | 646,524 | Common | SOLE |
| 92790C104 | VRDN | VIRIDIAN THERAPEUTICS INC | $9.6M | 2.14% | 736,595 | Common | SOLE |
| 82686Q101 | SLN | SILENCE THERAPEUTICS PLC | $9.0M | 2.02% | 476,200 | Common | SOLE |
| 032724106 | ANAB | ANAPTYSBIO INC | $9.0M | 2.01% | 357,733 | Common | SOLE |
| G3855L106 | GHRS | GH RESEARCH PLC | $6.7M | 1.49% | 572,665 | Common | SOLE |
| 19240Q201 | COGT | COGENT BIOSCIENCES INC | $6.7M | 1.49% | 790,440 | Common | SOLE |
| 929033108 | — | VOR BIOPHARMA INC | $6.4M | 1.42% | 6,361,723 | Common | SOLE |
| 810648105 | SCPH | SCPHARMACEUTICALS INC | $5.2M | 1.17% | 1,200,647 | Common | SOLE |
| 75120L100 | — | RALLYBIO CORP | $4.9M | 1.09% | 3,630,724 | Common | SOLE |
| 746964105 | QTTB | Q32 BIO INC | $4.5M | 1.01% | 251,994 | Common | SOLE |
| 00773U207 | AVU0 | ADVERUM BIOTECHNOLOGIES INC | $3.7M | 0.83% | 541,666 | Common | SOLE |
| 59045L106 | — | MERSANA THERAPEUTICS INC | $2.6M | 0.59% | 1,305,000 | Common | SOLE |
| 98943L107 | ZNTL | ZENTALIS PHARMACEUTICALS INC | $2.0M | 0.45% | 490,000 | Common | SOLE |
| 171757206 | CDTX | CIDARA THERAPEUTICS INC | $677,297 | 0.15% | 56,725 | Common | SOLE |
| 30233G209 | EYPT | EYEPOINT PHARMACEUTICALS INC | $435,000 | 0.10% | 50,000 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.